Stanford, UCSF researchers home in on key gene in multiple sclerosis progression

November 22, 2001

Stanford, Calif. - A critical gene, osteopontin, which is involved in the development of multiple sclerosis, has been identified by researchers at Stanford University Medical Center and the University of California San Francisco. Osteopontin is already known to be a factor in the inflammatory immune response characteristic of MS, but now researchers believe it may be positioned at a number of checkpoints in the progression of the disease. The findings could lead to targeted new therapies for MS in the future.

"The motivation for the study was the genomic application of Sutton's law," said Larry Steinman, MD, professor of neurology at Stanford. "Sutton's law" refers to a bank robber who, upon being asked why he robbed banks, answered, "Because that's where the money is." For Steinman and Jorge Oksenberg, PhD, associate professor of neurology at UCSF, the logic in examining autopsied brains from MS patients to learn about the disease is clear. "It's where the money is," said Steinman.

According to Steinman, collaboration with UCSF on this project was "a direct extension of a 10-year adventure looking at gene expression in the inflamed multiple sclerosis brain to see what's going on in the course of this disease." Steinman and Oksenberg, a former postdoctoral fellow with Steinman at Stanford, shared senior authorship on the paper explaining their findings, which appeared in the Nov. 23, 2001 issue of Science.

With large-scale sequencing, they created a gene library from the brains of people with MS, looking for genes that appeared most often. "We found an abundance of osteopontin in the multiple sclerosis brains - the equivalent of a dozen or more volumes," said Steinman, likening the genes to books in a library.

In MS, inflammation of nerve tissue destroys the myelin covering of nerve cell axons, leaving areas of scar tissue. This patchy loss of myelin in the brain and spinal cord slows communication between nerve cells, leading to symptoms such as muscle spasms, weakness, sensory deficits and visual disturbances.

Two important pieces of evidence presented in the paper indicate that in an experimental model of MS, the degree of expression of osteopontin may be related to the severity of the disease. First, the researchers determined that osteopontin expression varies with the phase of the disease. By inducing an autoimmune disease in rodents similar to MS in humans, they were able to show that osteopontin expression is most prominent in nerve cells near sites of active lesions during acute disease and relapse, but not during remission.

Second, using genetically altered mice lacking osteopontin, they confirmed that osteopontin affects the course of the disease, demonstrating that manifestations of the disease were significantly less severe in osteopontin-deficient mice. The percentage of remissions was much higher in the osteopontin-deficient mice. Moreover, there were no disease-related deaths in this group. It was suggested that osteopontin may influence the evolution of the disease, determining whether relapses and remissions develop.

"With this finding, a major piece of the puzzle is in place," said Oksenberg, "but there is much more work to be done." Steinman added that in addition to osteopontin, a number of other genes found warrant further examination. "We have identified the titles but haven't yet read the contents," he said.

MS affects approximately one million people worldwide, with women being twice as likely as men to have the disease. At present, MS is incurable and the cause is unknown. The underlying problem may involve the inability of the body's immune system to distinguish "self" molecules from foreign molecules.
Postdoctoral fellows Dorthee Chabas at Stanford and Sergio Baranzini at UCSF were co-first authors on this study. Chabas carried out the studies in mice and Baranzini analyzed the large-scale gene sequences. Renu Heller is also a co-senior author for her role in organizing the work through her position at Roche Biosciences.

This study was funded by the National Institutes of Health; the National Multiple Sclerosis Society; the Susan G. Komen Foundation; the Association Francaise Contre les Myopathies; the Ligue Francaise Contre La Sclerose En Plaques; the Assistance Publique des Hopitaux de Paris; and Roche Biosciences.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital. For more information, please visit the Web site of the medical center's Office of News and Public Affairs at

Stanford University Medical Center

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to